Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments Acurx Pharmaceuticals provides a comprehensive update on their financial performance for 2025, including innovative trials, strategic advancements in antibiotic development, and significant operational achievements.

Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotics

Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program Acurx Pharmaceuticals has unveiled a new clinical trial program for Ibezapolstat targeting recurrent CDI, aiming to transform treatment standards and efficacy.

Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #CDI_Treatment

Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology Acurx Pharmaceuticals has been awarded a new patent for its cutting-edge DNA Polymerase IIIC inhibitors, strengthening its IP in antibiotic development.

Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #DNA_Polymerase_IIIC

Acurx Pharmaceuticals Shows Progress in Antibiotic Development in Q3 2025 Results Acurx Pharmaceuticals unveiled their third-quarter results, highlighting advancements in antibiotic development and patent approvals, while addressing financials.

Acurx Pharmaceuticals Shows Progress in Antibiotic Development in Q3 2025 Results #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotics

Acurx Pharmaceuticals Publishes Landmark Study on New Antibiotic Mechanism Targeting Priority Pathogens Acurx Pharmaceuticals unveils groundbreaking research on DNA polymerase IIIC inhibitors, showcasing promising new antibiotics against severe bacterial infections.

Acurx Pharmaceuticals Publishes Landmark Study on New Antibiotic Mechanism Targeting Priority Pathogens #USA #Ibezapolstat #Acurx #Staten_Island #Antibiotics

Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025 Acurx provided groundbreaking findings on its DNA pol IIIC inhibitor, ibezapolstat, which shows selective antibacterial properties, at IDWeek 2025.

Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025 #USA #Atlanta #Ibezapolstat #Acurx_Pharmaceuticals #DNA_pol_IIIC

Acurx Pharmaceuticals Receives EMA Approval for Pediatric Use of Ibezapolstat Against C. difficile Acurx Pharmaceuticals has received a positive opinion from the EMA for its Pediatric Investigation Plan for ibezapolstat, a critical treatment for C. difficile infections in children.

Acurx Pharmaceuticals Receives EMA Approval for Pediatric Use of Ibezapolstat Against C. difficile #United_States #Ibezapolstat #C._difficile #Staten_Island #Acurx_Pharmaceuticals

Acurx Pharmaceuticals Secures $2.67 Million by Exercising Warrants Acurx Pharmaceuticals has announced a successful warrant inducement agreement, generating $2.67 million in proceeds in a bid to bolster its antibiotic development efforts.

Acurx Pharmaceuticals Secures $2.67 Million by Exercising Warrants #United_States #biopharmaceuticals #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals

Acurx's Ibezapolstat Shows Promising Results in Latest Clinical Trial for C. Difficile Infection Treatment Acurx Pharmaceuticals announces positive findings for Ibezapolstat, its innovative antibiotic for treating C. difficile infection, from a Phase 2b clinical trial. This promising data underlines the drug's potential.

Acurx's Ibezapolstat Shows Promising Results in Latest Clinical Trial for C. Difficile Infection Treatment #USA #Ibezapolstat #C._difficile #Staten_Island #Acurx_Pharmaceuticals

New research article

Efficacy, safety, pharmacokinetics, and associated #microbiome changes of #ibezapolstat compared with #vancomycin in adults with #Clostridioides difficile infection

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #MicroSky #Cdiff #OpenAccess #OA

Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference Acurx Pharmaceuticals showcased significant findings from its research on novel antibiotics at a leading scientific conference, advancing the fight against persistent infections.

Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference #United_States #New_York #Ibezapolstat #Acurx_Pharmaceuticals #DNA_pol_IIIC

Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates Acurx Pharmaceuticals delivers an encouraging financial report for Q1 2025, highlighting advancements in antibiotic development and strategic partnerships.

Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates #USA #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotic_Development

Acurx Pharmaceuticals Set to Present at A.G.P. Healthcare Showcase on New Antibiotics Acurx Pharmaceuticals announces participation in the A.G.P. Healthcare Company Showcase, highlighting their innovative antibiotics for challenging bacterial infections.

Acurx Pharmaceuticals Set to Present at A.G.P. Healthcare Showcase on New Antibiotics #USA #Ibezapolstat #Acurx_Pharmaceuticals #Antibiotics #Staten_Island,_NY

Acurx Pharmaceuticals Unveils Encouraging Fourth Quarter and Year-End Results for 2024 Acurx Pharmaceuticals shares positive results from Q4 2024 and provides updates on its innovative antibiotic, Ibezapolstat's efficacy against CDI.

Acurx Pharmaceuticals Unveils Encouraging Fourth Quarter and Year-End Results for 2024 #United_States #Ibezapolstat #C._difficile #Staten_Island #Acurx_Pharmaceuticals

Acurx Pharmaceuticals Completes $1.1 Million Stock Offering to Fund Future Developments Acurx Pharmaceuticals has closed a $1.1 million registered direct offering. This funding will support their innovative antibiotic development efforts.

Acurx Pharmaceuticals Completes $1.1 Million Stock Offering to Fund Future Developments #Ibezapolstat #Acurx_Pharmaceuticals #ACXP

Acurx's Innovative Research Differentiates Ibezapolstat's Impact on Gut Microbiome Acurx Pharmaceuticals published groundbreaking results showing how Ibezapolstat uniquely affects the gut microbiome, distinguishing it from other antibiotics used for CDI.

Acurx's Innovative Research Differentiates Ibezapolstat's Impact on Gut Microbiome #USA #Ibezapolstat #Acurx #Staten_Island #CDI

Acurx Pharmaceuticals Revels in Positive In-Silico Findings on Ibezapolstat's Efficacy for CDI Treatment Acurx Pharmaceuticals has unveiled promising findings from their in-silico study on ibezapolstat, showcasing its potential to restore gut microbiome in CDI treatment.

Acurx Pharmaceuticals Revels in Positive In-Silico Findings on Ibezapolstat's Efficacy for CDI Treatment #USA #Ibezapolstat #Acurx #Staten_Island #CDI

Acurx Pharmaceuticals Expands Patent Portfolio in Japan for Antibiotic Development Acurx Pharmaceuticals has secured a new patent in Japan for DNA Polymerase IIIC inhibitors, advancing its innovative antibiotics targeting serious bacterial infections.

Acurx Pharmaceuticals Expands Patent Portfolio in Japan for Antibiotic Development #Japan #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #DNA_Polymerase_IIIC

Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class Acurx Pharmaceuticals has successfully closed a $2.5 million direct offering of its common stock, designed to fund the development of innovative antibiotics targeting resistant bacterial infections.

Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotic_Development

Acurx Pharmaceuticals Executes $2.5 Million Direct Stock Offering to Advance Antibiotic Development Acurx Pharmaceuticals announced a direct stock offering aimed at raising $2.5 million to support its development of innovative antibiotics targeting resistant bacterial infections.

Acurx Pharmaceuticals Executes $2.5 Million Direct Stock Offering to Advance Antibiotic Development #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotics

Acurx Pharmaceuticals Steps Forward with Ibezapolstat Phase 3 Trials for C. Difficile Infections Following EMA Guidance Acurx Pharmaceuticals has received positive feedback from the EMA, paving the way for Phase 3 trials of Ibezapolstat to combat C. difficile infections.

Acurx Pharmaceuticals Steps Forward with Ibezapolstat Phase 3 Trials for C. Difficile Infections Following EMA Guidance #United_States #Ibezapolstat #C._difficile #Staten_Island #Acurx_Pharmaceuticals

Acurx Pharmaceuticals Advances Ibezapolstat to Phase 3 Trials for C. Difficile Infections Following Regulatory Endorsements Acurx Pharmaceuticals is gearing up for international Phase 3 clinical trials for its antibiotic Ibezapolstat, targeting C. difficile infections, following positive feedback from the FDA and EMA.

Acurx Pharmaceuticals Advances Ibezapolstat to Phase 3 Trials for C. Difficile Infections Following Regulatory Endorsements #USA #Ibezapolstat #Acurx #C._difficile #Staten_Island